Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα
Authors:
- Seunghee HongSHSeunghee Hong
- Sungwoo HongSHSungwoo Hong
- 1 December 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (23) , 6977-6981
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Science and Technology (2011-0016436, 2011-0020322, 2011-0026680, NRF-2011-0003609)
- National Research Foundation of Korea
This publication has 24 references indexed in Scilit:
- Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic StabilityJournal of Medicinal Chemistry, 2011
- A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in miceProceedings of the National Academy of Sciences, 2010
- PIKing the right isoform: the emergent role of the p110β subunit in breast cancerVirchows Archiv, 2010
- The role of PI 3‐kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cellsThe Prostate, 2010
- PTEN-deficient cancers depend on PIK3CBProceedings of the National Academy of Sciences, 2008
- Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocketBiochemical Journal, 2008
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and diseaseJournal of Molecular and Cellular Cardiology, 2004
- The Phosphoinositide 3-Kinase PathwayScience, 2002